- Home
- SGLY vs MBIO Comparison
SGLY vs MBIO Comparison
Compare SGLY & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- MBIO
- Stock Information
- Founded
- SGLY 2001
- MBIO 2015
- Country
- SGLY United States
- MBIO United States
- Employees
- SGLY N/A
- MBIO N/A
- Industry
- SGLY
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- SGLY
- MBIO Health Care
- Exchange
- SGLY Nasdaq
- MBIO Nasdaq
- Market Cap
- SGLY 4.1M
- MBIO 4.7M
- IPO Year
- SGLY 2008
- MBIO N/A
- Fundamental
- Price
- SGLY $0.93
- MBIO $1.69
- Analyst Decision
- SGLY
- MBIO
- Analyst Count
- SGLY 0
- MBIO 0
- Target Price
- SGLY N/A
- MBIO N/A
- AVG Volume (30 Days)
- SGLY 12.0K
- MBIO 208.3K
- Earning Date
- SGLY 08-26-2025
- MBIO 08-08-2025
- Dividend Yield
- SGLY N/A
- MBIO N/A
- EPS Growth
- SGLY N/A
- MBIO N/A
- EPS
- SGLY N/A
- MBIO N/A
- Revenue
- SGLY $2,172,036.00
- MBIO N/A
- Revenue This Year
- SGLY N/A
- MBIO N/A
- Revenue Next Year
- SGLY N/A
- MBIO N/A
- P/E Ratio
- SGLY N/A
- MBIO N/A
- Revenue Growth
- SGLY N/A
- MBIO N/A
- 52 Week Low
- SGLY $0.54
- MBIO $0.89
- 52 Week High
- SGLY $7.65
- MBIO $21.95
- Technical
- Relative Strength Index (RSI)
- SGLY 40.41
- MBIO 48.03
- Support Level
- SGLY $0.92
- MBIO $1.41
- Resistance Level
- SGLY $1.00
- MBIO $1.88
- Average True Range (ATR)
- SGLY 0.04
- MBIO 0.15
- MACD
- SGLY -0.00
- MBIO 0.00
- Stochastic Oscillator
- SGLY 11.11
- MBIO 60.42
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.